KCNA7抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela cells, mouse kidney tissue, Primary antibody: P04988(KCNA7 Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P04988(KCNA7 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P04988(KCNA7 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The KCNA7 antibody targets the potassium voltage-gated channel subfamily A member 7 (KCNA7), a protein encoded by the *KCNA7* gene. This channel belongs to the Shaker-related potassium channel family, which regulates action potential repolarization in excitable cells. KCNA7 forms tetrameric channels that facilitate potassium ion efflux, contributing to cellular electrical stability, particularly in cardiac and neuronal tissues. Structurally, it contains six transmembrane segments (S1-S6), with the S4 region acting as a voltage sensor.

KCNA7 is expressed in the heart, skeletal muscle, and brain, where it influences excitability and signaling. Dysregulation or mutations in KCNA7 are linked to arrhythmias, neurological disorders, and some cancers. Antibodies against KCNA7 are critical tools for studying its expression, localization, and functional roles. They are used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate channel distribution in tissues or disease models.

Research on KCNA7 antibodies has advanced understanding of potassium channelopathies and potential therapeutic targets. For example, altered KCNA7 expression is observed in atrial fibrillation, suggesting its role in cardiac electrical abnormalities. These antibodies also aid in exploring interactions with auxiliary subunits or drugs modulating channel activity. Commercial KCNA7 antibodies are typically validated for specificity using knockout controls or peptide-blocking assays. Ongoing studies focus on clarifying its physiological impact and translational relevance in channel-related diseases.